GILD vs IMNM
GILD: A leading biopharmaceutical innovator specializing in life-saving HIV therapies and complex CAR T-cell cancer treatments. IMNM: Immunome is a clinical-stage biotechnology company leveraging a proprietary platform to discover and develop novel, targeted oncology therapeutics.
Side-by-side fundamentals
| Metric | GILD | IMNM | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $146.12 | $28.52 | |
| Market cap as of 2026-08-24 | $181.2B | $3.2B | |
| P/E as of 2026-08-24 | 19.96 | n/a | |
| PEG as of 2026-08-24 | 2.53 | n/a | |
| Net margin as of 2026-08-24 | -10.6% | -1687.1% | GILD higher |
| Gross margin as of 2026-08-24 | +79.6% | n/a | |
| Operating margin as of 2026-08-24 | -8.2% | -1784.1% | GILD higher |
| ROE as of 2026-08-24 | -16.3% | -51.1% | GILD higher |
| ROA as of 2026-08-24 | -5.8% | -47.3% | GILD higher |
| Debt / equity as of 2026-08-24 | 2.22 | 0.00 | IMNM lower |
| Revenue growth (YoY) as of 2026-08-24 | +5.5% | -63.3% | GILD higher |
| Revenue CAGR (3y) SEC XBRL | +2.6% | -29.6% | GILD higher |
| Dividend yield as of 2026-08-24 | +4.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-24 | 0.34 | 2.54 | |
| 1-year return as of 2026-08-21 close | +25.8% | +186.6% | IMNM higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.